Connor, Clark & Lunn Investment Management (CC&L)
LOGC

Connor, Clark & Lunn Investment Management (CC&L)’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,974
Closed -$25K – 1280
2021
Q4 		$25K Buy
+10,974
New +$37.1K ﹤0.01% 1053

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LOGC Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 10,974 shares — an estimated $25K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LOGC in Q4 2021 and held it in 1 quarter. The position peaked at $25K in Q4 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 10,974 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $25K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s LogicBio Therapeutics, Inc. Common Stock position peaked at $25K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.